This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
Placebo can reduce feelings of guilt, even when administered openly
Guilt is an uncomfortable feeling and can be burdensome. Researchers at the University of Basel have shown that placebos can help reduce feelings of guilt, even when the placebo is administered openly.
People don't always behave impeccably in relationships with others. When we notice that this has inadvertently caused harm, we often feel guilty. This is an uncomfortable feeling and motivates us to take remedial action, such as apologizing or owning up.
This is why guilt is considered an important moral emotion, as long as it is adaptive—in other words, appropriate and in proportion to the situation. "It can improve interpersonal relationships and is therefore valuable for social cohesion," says Dilan Sezer, researcher at the Division of Clinical Psychology and Psychotherapy at the University of Basel.
Whether feelings of guilt can be reduced by taking placebos is something that researchers at the Faculty of Psychology at the University of Basel have been exploring. Their findings have now been published in the journal Scientific Reports.
Open-label placebos work
In order to awaken their feelings of guilt, test subjects in the study were asked to write about a time when they had disregarded important rules of conduct, or treated someone close to them unfairly, hurt or even harmed them. The idea was that the study participants should still feel bad about the chosen situation.
Participants were then randomized to three conditions: Participants in one group were given placebo pills while being deceptively told that it was a real medication; the participants in another group were told that they were given a placebo. Both groups were told that what they had been given would be effective against feelings of guilt. The control group was given no treatment at all. The results showed that feelings of guilt were significantly reduced in both placebo groups compared to those without medication.
This was also the case when the subjects knew they had been given a placebo. "Our study therefore supports the intriguing finding that placebos work even when they are administered openly, and that explanation of the treatment is key to its effectiveness," states the study's lead author, Dilan Sezer. Participants in this study were all healthy, had no psychiatric disorders and were not being treated with psychotropics.
Clinical applicability not yet proven
Where feelings of guilt are irrational and continue for longer periods of time, they are considered maladaptive—in other words, disproportionate. These emotions can affect people's health and are also—among other things—a common symptom of depression.
Scientific studies have shown that placebo effects can be powerful in treating depression. But the finding that open-label placebos can also be useful for such strong emotions as guilt is new. It stands to reason, says Sezer, that we should try to harness these effects to help those affected. "The administering of open-label placebos, in particular, is a promising approach, as it preserves patient autonomy by allowing patients to be fully aware of how the intervention works."
The results of the study are an initial promising step in the direction of symptom-specific and more ethical treatments for psychological complaints using open-label placebos, Sezer continues.
Further research will need to be done into whether it is possible to treat maladaptive guilt with placebos. And it is still not known whether similar effects are also possible with other feeling states. For Sezer, one thing is certain: "Using open-label placebos would be an inexpensive and straightforward treatment option for many psychological and physical complaints."
More information: Dilan Sezer et al, Deceptive and open-label placebo effects in experimentally induced guilt: a randomized controlled trial in healthy subjects, Scientific Reports (2022). DOI: 10.1038/s41598-022-25446-1